Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Joseph P. Lyssikatos Sells 12,500 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 12,500 shares of the firm’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $20.61, for a total value of $257,625.00. Following the completion of the sale, the insider now owns 1,002,688 shares of the company’s stock, valued at approximately $20,665,399.68. This represents a 1.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Enliven Therapeutics Stock Up 0.8 %

Shares of Enliven Therapeutics stock opened at $21.08 on Monday. The stock’s fifty day moving average is $21.31 and its two-hundred day moving average is $23.78. Enliven Therapeutics, Inc. has a 52 week low of $15.96 and a 52 week high of $30.03. The company has a market capitalization of $1.03 billion, a PE ratio of -11.09 and a beta of 1.04.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. As a group, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Trading of Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its stake in Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after buying an additional 1,114 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Enliven Therapeutics in the 4th quarter valued at approximately $97,000. BNP Paribas Financial Markets purchased a new stake in Enliven Therapeutics during the 4th quarter worth approximately $112,000. ExodusPoint Capital Management LP acquired a new position in Enliven Therapeutics during the 4th quarter valued at approximately $200,000. Finally, Brevan Howard Capital Management LP purchased a new position in shares of Enliven Therapeutics in the fourth quarter worth $228,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ELVN. BTIG Research began coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 target price on the stock. HC Wainwright increased their price objective on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $38.75.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.